Page 127 - Read Online

Gomaa et al. Advanced HCC: current and potential therapies

hepatocellular carcinoma. N Engl J Med 2008;359:378-90. Furuse J, Geschwind J, Guevara LL, Papandreou C. GIDEON (Global
3. Kudo M. A new era of systemic therapy for hepatocellular carcinoma Investigation of therapeutic DEcisions in hepatocellular carcinoma
with regorafenib and lenvatinib. Liver Cancer 2017;6:177-84. and of its treatment with sorafeNib): second interim analysis. Int J
4. Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for Clin Pract 2014;68:609-17.
hepatocellular carcinoma. J Hepatol 2012;56:464-73. 19. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J.
5. Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert Plasma biomarkers as predictors of outcome in patients with advanced
H. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300.
hepatocellular carcinoma. World J Gastroenterol 2016;22:253-61. 20. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L,
6. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MDC, Sala Rizzo S, Venditti O, Frezza AM, Caraglia M. Early skin toxicity
M, Brú C, Rodés J, Bruix J. Natural history of untreated nonsurgical as a predictive factor for tumor control in hepatocellular carcinoma
hepatocellular carcinoma: rationale for the design and evaluation of patients treated with sorafenib. Oncologist 2010;15:85-92.
therapeutic trials. Hepatology 1999;29:62-7. 21. Otsuka T, Eguchi Y, Kawazoe S, Yanagita K, Ario K, Kitahara
7. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen K, Kawasoe H, Kato H, Mizuta T. Skin toxicities and survival in
PJ, Kudo M, Johnson P, Wagner S, Orsini LS. Global patterns of advanced hepatocellular carcinoma patients treated with sorafenib.
hepatocellular carcinoma management from diagnosis to death: the Hepatol Res 2012;42:879-86.
BRIDGE Study. Liver Int 2015;35:2155-66. 22. Reig M, Torres F, RodriguezLope C, Forner A, LLarch N, Rimola
8. Yang JD, Mohamed EA, Aziz AO, Shousha HI, Hashem MB, Nabeel J, Darnell A, Ríos J, Ayuso C, Bruix J. Early dermatologic adverse
MM, Abdelmaksoud AH, Elbaz TM, Afihene MY, Duduyemi events predict better outcome in HCC patients treated with sorafenib.
BM. Characteristics, management, and outcomes of patients with J Hepatol 2014;61:318-24.
hepatocellular carcinoma in Africa: a multicountry observational 23. Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten
study from the Africa Liver Cancer Consortium. Lancet TM. Diarrhea is a positive outcome predictor for sorafenib treatment
Gastroenterol Hepatol 2017;2:103-11. of advanced hepatocellular carcinoma. Oncology 2013;84:6-13.
9. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, 24. Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular
Montalto G. Targeted therapy for hepatocellular carcinoma: novel carcinoma: hypertension as a potential surrogate marker for efficacy.
agents on the horizon. Oncotarget 2012;3:236-60. Am J Clin Oncol 2013;36:319-24.
10. Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura 25. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg
S, Kasai C, Kusagawa S, Yoneda M, Yamamoto N. Sorafenib and R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M.
TRAIL have synergistic effect on hepatocellular carcinoma. Int J Sorafenib in unresectable hepatocellular carcinoma from mild to
Oncol 2013;42:101-8. advanced stage liver cirrhosis. Oncologist 2009;14:70-6.
11. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng 26. Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M,
J, Ye S, Yang TS. Efficacy and safety of sorafenib in patients in the Barbara M, Basso M, Vavassori S, Craxì A, Grieco A. Predictors
Asia-Pacific region with advanced hepatocellular carcinoma: a phase of survival in patients with advanced hepatocellular carcinoma who
III randomised, double-blind, placebo-controlled trial. Lancet Oncol permanently discontinued sorafenib. Hepatology 2015;62:784-91.
2009;10:25-34. 27. Reig M, Rimola J, Torres F, Darnell A, RodriguezLope C, Forner
12. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung A, LLarch N, Ríos J, Ayuso C, Bruix J. Postprogression survival
HC, Song X, Xu J, Poggi G. Sunitinib versus sorafenib in advanced of patients with advanced hepatocellular carcinoma: rationale for
hepatocellular cancer: results of a randomized phase III trial. J Clin second-line trial design. Hepatology 2013;58:2023-31.
Oncol 2013;31:4067-75. 28. Finn RS, Cheng AL, Ikeda K, Kudo M, Tamai T, Dutcus CE,
13. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Younger S, Han KH, Qin S, Raymond E. A multicenter, open-label,
Hu TH, Heo J, Xu J. Brivanib versus sorafenib as first-line therapy phase 3 trial to compare the efficacy and safety of lenvatinib (E7080)
in patients with unresectable, advanced hepatocellular carcinoma: versus sorafenib in first-line treatment of subjects with unresectable
results from the randomized phase III BRISK-FL study. J Clin Oncol hepatocellular carcinoma. J Clin Oncol 2014;32 suppl:tps4153.
2013;31:3517-24. 29. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M,
14. Zhu AX, Rosmorduc O, Evans TJ, Ross PJ, Santoro A, Carrilho Yokosuka O, Rosmorduc O, Breder V. Regorafenib for patients with
FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM. SEARCH: a phase III, hepatocellular carcinoma who progressed on sorafenib treatment
randomized, double-blind, placebo-controlled trial of sorafenib plus (RESORCE): a randomised, double-blind, placebo-controlled, phase
erlotinib in patients with advanced hepatocellular carcinoma. J Clin 3 trial. Lancet 2017;389:56-66.
Oncol 2015;33:559-66. 30. Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T,
15. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Tamai T, Suzuki T, Hisai T, Hayato S. Phase 2 study of lenvatinib
Kang YK, Chen PJ, Toh HC. Linifanib versus sorafenib in patients in patients with advanced hepatocellular carcinoma. J Gastroenterol
with advanced hepatocellular carcinoma: results of a randomized 2017;52:512-9.
phase III trial. J Clin Oncol 2015;33:172-9. 31. Positive Topline Results of Large Phase 3 Trial Show Eisai’s
16. Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang Lenvatinib Meets Primary Endpoint in Unresectable Hepatocellular
TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M. Randomized, Carcinoma. Available from: http://eisai.mediaroom.com/2017-
open-label phase 2 study comparing frontline dovitinib versus 01-25-Positive-Topline-Results-of-Large-Phase-3-Trial-Show-
sorafenib in patients with advanced hepatocellular carcinoma. Eisais-Lenvatinib-Meets-Primary-Endpoint-in-Unresectable-
Hepatology 2016;64:774-84. Hepatocellular-Carcinoma. [Last accessed on June 1, 2017].
17. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, 32. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF,
Cammà C, Colombo M. Field-practice study of sorafenib therapy for Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J,
hepatocellular carcinoma: a prospective multicenter study in Italy. Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo
Hepatology 2011;54:2055-63. M. Ramucirumab versus placebo as second-line treatment in patients
18. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, with advanced hepatocellular carcinoma following first-line therapy
Hepatoma Research ¦ Volume 3 ¦ June 15, 2017 119